These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21455230)

  • 1. Fresh from the pipeline. Ticagrelor.
    Huber K; Hamad B; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Apr; 10(4):255-6. PubMed ID: 21455230
    [No Abstract]   [Full Text] [Related]  

  • 2. Ticagrelor approved for acute coronary syndrome.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1568. PubMed ID: 21856798
    [No Abstract]   [Full Text] [Related]  

  • 3. Ticagrelor: a novel oral antiplatelet agent.
    Huang NS; Master HH; Fusco JA; Park ZH
    Consult Pharm; 2010 Nov; 25(11):745-55. PubMed ID: 21138823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor in ST-elevation myocardial infarction.
    Sgueglia GA; Tarantini G; Niccoli G
    Curr Vasc Pharmacol; 2012 Jul; 10(4):458-62. PubMed ID: 22339257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor: the silence of the platelets.
    Laine M; Paganelli F; Bonello L
    Expert Opin Pharmacother; 2013 Feb; 14(2):151-3. PubMed ID: 23294190
    [No Abstract]   [Full Text] [Related]  

  • 6. Ticagrelor for the treatment of arterial thrombosis.
    Gurbel PA; Kereiakes DJ; Tantry US
    Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
    Gaglia MA; Waksman R
    Circulation; 2011 Feb; 123(4):451-6. PubMed ID: 21242480
    [No Abstract]   [Full Text] [Related]  

  • 9. Ticagrelor: a novel drug for an old problem.
    Rognoni A; Cavallino C; Lupi A; Secco GG; Veia A; Bacchini S; Rosso R; Brunelleschi S; Rametta F; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2014; 9(1):51-7. PubMed ID: 25174338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor for the treatment of peripheral arterial disease.
    Chong AY; So DY
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1737-43. PubMed ID: 25376000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
    Teng R
    Clin Pharmacokinet; 2012 May; 51(5):305-18. PubMed ID: 22489610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
    Crouch MA; Colucci VJ; Howard PA; Spinler SA
    Ann Pharmacother; 2011 Sep; 45(9):1151-6. PubMed ID: 21852599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
    Varenhorst C; James S
    Curr Cardiol Rep; 2012 Aug; 14(4):486-92. PubMed ID: 22535473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
    James SK; Pieper KS; Cannon CP; Storey RF; Becker RC; Steg PG; Wallentin L; Harrington RA;
    Stroke; 2013 May; 44(5):1477-9. PubMed ID: 23572474
    [No Abstract]   [Full Text] [Related]  

  • 16. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor for acute coronary syndromes.
    Bansilal S; Bonaca MP; Sabatine MS
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1473-84. PubMed ID: 24147518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests.
    Dillinger JG; Manzo Silberman S; Bal dit Sollier C; Amsallem M; Sideris G; Voicu S; Henry P; Drouet L
    Int J Cardiol; 2014 Sep; 176(2):557-9. PubMed ID: 25074556
    [No Abstract]   [Full Text] [Related]  

  • 19. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
    Wijeyeratne YD; Joshi R; Heptinstall S
    Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
    Wang H; Qi J; Li Y; Tang Y; Li C; Li J; Han Y
    Br J Clin Pharmacol; 2018 Jan; 84(1):88-96. PubMed ID: 28921624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.